Trial of zolpidem, eszopiclone, and other gaba agonists in a patient with progressive supranuclear palsy

Case Reports in Medicine

Volumn 2014, Issue , 2014, Pages

  Chang, Andrew Young ^a   Weirich, Erica ^a,b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b PALO ALTO MEDICAL FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ESZOPICLONE; FLURAZEPAM; TEMAZEPAM; TIZANIDINE; TRIAZOLAM; ZOLPIDEM;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; FACIAL EXPRESSION; FEMALE; HUMAN; INFORMED CONSENT; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; MUSCLE SPASM; PROGRESSIVE SUPRANUCLEAR PALSY; SPEECH; SUSTAINED DRUG RELEASE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84977110246     PISSN: 16879627     EISSN: 16879635     Source Type: Journal    
DOI: 10.1155/2014/107064     Document Type: Article

References (19)

1. Steel J. C., Richardson J. C., Olszewsk J., Progressive Supranuclear Palsy, a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Archives of Neurology 1964 10 333 359 10.1001/archneur.1964.00460160003001 2-s2.0-75549116708
2. Foster N. L., Minoshima S., Johanns J., Little R., Heumann M. L., Kuhl D. E., Gilman S., PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology 2000 54 9 1768 1773 10.1212/WNL.54.9.1768 2-s2.0-0034624924
3. Levy R., Ruberg M., Herrero M. T., Villares J., Javoy-Agid F., Agid Y., Hirsch E. C., Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy: an in situ hybridization study of GAD67 messenger RNA. Neurology 1995 45 1 127 134 10.1212/WNL.45.1.127 2-s2.0-0028816456
4. Bensimon G., Ludolph A., Agid Y., Vidailhet M., Payan C., Leigh P. N., Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS Study. Brain 2009 132 part 1 156 171 10.1093/brain/awn291 2-s2.0-58849122658
5. Frattali C. M., Sonies B. C., Chi-Fishman G., Litvan I., Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: a pilot study. Dysphagia 1999 14 3 165 168 10.1007/PL00009600 2-s2.0-0032986361
6. Rascol O., Sieradzan K., Peyro-Saint-Paul H., Thalamas C., Brefel-Courbon C., Senard J. M., Ladure P., Montastruc J. L., Lees A., Efaroxan, an α-2 antagonist, in the treatment of progressive supranuclear palsy. Movement Disorders 1998 13 4 673 676 10.1002/mds.870130411 2-s2.0-0031853557
7. Langer S. Z., Arbilla S., Scatton B. V., Niddam R., Dubois A., Receptors involved in the mechanism of action of zolpidem. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach 1998 New York, NY, USA Raven Press 55 70
8. Daniele A., Moro E., Bentivoglio A. R., Zolpidem in progressive supranuclear palsy. The New England Journal of Medicine 1999 341 7 543 544 10.1056/NEJM199908123410721 2-s2.0-0033549784
9. Mayr B. J., Bonelli R. M., Niederwieser G., Költringer P., Reisecker F., Zolpidem in progressive supranuclear palsy. European Journal of Neurology 2002 9 2 184 185 10.1046/j.1468-1331.2002.0354g.x 2-s2.0-0036048193
10. Cotter C., Armytage T., Crimmins D., The use of zolpidem in the treatment of progressive supranuclear palsy. Journal of Clinical Neuroscience 2010 17 3 385 386 10.1016/j.jocn.2009.05.038 2-s2.0-75349104161
11. Cohen L., Chaaban B., Habert M. O., Transient improvement of aphasia with zolpidem. The New England Journal of Medicine 2004 350 9 949 950 10.1056/NEJM200402263500922 2-s2.0-1342268092
12. Shadan F. F., Poceta J. S., Kline L. E., Zolpidem for postanoxic spasticity. Southern Medical Journal 2004 97 8 791 792 10.1097/00007611-200408000-00025 2-s2.0-4243166989
13. Clauss R., Sathekge M., Nel W., Transient improvement of spinocerebellar ataxia with zolpidem. The New England Journal of Medicine 2004 351 5 511 512 10.1056/NEJM200407293510522 2-s2.0-3342931170
14. Clauss R. P., Nel H. W., Evidence for Zo lpidem efficacy in brain damage. South African Family Practice 2011 47 3 49 50
15. Cohen S. I., Duong T. T., Increased arousal in a patient with anoxic brain injury after administration of zolpidem. The American Journal of Physical Medicine and Rehabilitation 2008 87 3 229 231 10.1097/PHM.0b013e318161971b 2-s2.0-39749157026
16. Folstein M. F., Folstein S. E., McHugh P. R., "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975 12 3 189 198
17. Neubauer D. N., The evolution and development of insomnia pharmacotherapies. Journal of Clinical Sleep Medicine 2007 3 5 supplement S11 S16 2-s2.0-34548496295
18. Hanson S. M., Morlock E. V., Satyshur K. A., Czajkowski C., Structural requirements for eszopiclone and zolpidem binding to the γ -aminobutyric acid type-A (GABAA) receptor are different. Journal of Medicinal Chemistry 2008 51 22 7243 7252 10.1021/jm800889m 2-s2.0-56749163600
19. Flugy A., Gagliano M., Cannizzaro C., Novara V., Cannizzaro G., Antidepressant and anxiolytic effects of alprazolam versus the conventional antidepressant desipramine and the anxiolytic diazepam in the forced swim test in rats. European Journal of Pharmacology 1992 214 2-3 233 238 10.1016/0014-2999(92)90123-L 2-s2.0-0026557515